Cargando…

A clinical perspective of chitosan nanoparticles for infectious disease management

Infectious diseases and their effective management are still a challenge in this modern era of medicine. Diseases, such as the SARS-CoV-2, Ebola virus, and Zika virus, still put human civilization at peril. Existing drug banks, which include antivirals, antibacterial, and small-molecule drugs, are t...

Descripción completa

Detalles Bibliográficos
Autores principales: Dilnawaz, Fahima, Acharya, Sarbari, Kanungo, Anwesha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073797/
https://www.ncbi.nlm.nih.gov/pubmed/37362954
http://dx.doi.org/10.1007/s00289-023-04755-z
_version_ 1785019647466143744
author Dilnawaz, Fahima
Acharya, Sarbari
Kanungo, Anwesha
author_facet Dilnawaz, Fahima
Acharya, Sarbari
Kanungo, Anwesha
author_sort Dilnawaz, Fahima
collection PubMed
description Infectious diseases and their effective management are still a challenge in this modern era of medicine. Diseases, such as the SARS-CoV-2, Ebola virus, and Zika virus, still put human civilization at peril. Existing drug banks, which include antivirals, antibacterial, and small-molecule drugs, are the most advocated method for treatment, although effective but they still flounder in many instances. This calls for finding more effective alternatives for tackling the menace of infectious diseases. Nanoformulations are progressively being implemented for clinical translation and are being considered a new paradigm against infectious diseases. Natural polymers like chitosan are preferred to design nanoparticles owing to their biocompatibility, biodegradation, and long shelf-life. The chitosan nanoparticles (CNPs) being highly adaptive delivers contemporary prevention for infectious diseases. Currently, they are being used as antibacterial, drug, and vaccine delivery vehicles, and wound-dressing materials, for infectious disease treatment. Although the recruitment of CNPs in clinical trials associated with infectious diseases is minimal, this may increase shortly due to the sudden emergence of unknown pathogens like SARS-CoV-2, thus turning them into a panacea for the management of microorganisms. This review particularly focuses on the all-around application of CNPs along with their recent clinical applications in infectious disease management.
format Online
Article
Text
id pubmed-10073797
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-100737972023-04-05 A clinical perspective of chitosan nanoparticles for infectious disease management Dilnawaz, Fahima Acharya, Sarbari Kanungo, Anwesha Polym Bull (Berl) Review Paper Infectious diseases and their effective management are still a challenge in this modern era of medicine. Diseases, such as the SARS-CoV-2, Ebola virus, and Zika virus, still put human civilization at peril. Existing drug banks, which include antivirals, antibacterial, and small-molecule drugs, are the most advocated method for treatment, although effective but they still flounder in many instances. This calls for finding more effective alternatives for tackling the menace of infectious diseases. Nanoformulations are progressively being implemented for clinical translation and are being considered a new paradigm against infectious diseases. Natural polymers like chitosan are preferred to design nanoparticles owing to their biocompatibility, biodegradation, and long shelf-life. The chitosan nanoparticles (CNPs) being highly adaptive delivers contemporary prevention for infectious diseases. Currently, they are being used as antibacterial, drug, and vaccine delivery vehicles, and wound-dressing materials, for infectious disease treatment. Although the recruitment of CNPs in clinical trials associated with infectious diseases is minimal, this may increase shortly due to the sudden emergence of unknown pathogens like SARS-CoV-2, thus turning them into a panacea for the management of microorganisms. This review particularly focuses on the all-around application of CNPs along with their recent clinical applications in infectious disease management. Springer Berlin Heidelberg 2023-04-05 /pmc/articles/PMC10073797/ /pubmed/37362954 http://dx.doi.org/10.1007/s00289-023-04755-z Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Paper
Dilnawaz, Fahima
Acharya, Sarbari
Kanungo, Anwesha
A clinical perspective of chitosan nanoparticles for infectious disease management
title A clinical perspective of chitosan nanoparticles for infectious disease management
title_full A clinical perspective of chitosan nanoparticles for infectious disease management
title_fullStr A clinical perspective of chitosan nanoparticles for infectious disease management
title_full_unstemmed A clinical perspective of chitosan nanoparticles for infectious disease management
title_short A clinical perspective of chitosan nanoparticles for infectious disease management
title_sort clinical perspective of chitosan nanoparticles for infectious disease management
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073797/
https://www.ncbi.nlm.nih.gov/pubmed/37362954
http://dx.doi.org/10.1007/s00289-023-04755-z
work_keys_str_mv AT dilnawazfahima aclinicalperspectiveofchitosannanoparticlesforinfectiousdiseasemanagement
AT acharyasarbari aclinicalperspectiveofchitosannanoparticlesforinfectiousdiseasemanagement
AT kanungoanwesha aclinicalperspectiveofchitosannanoparticlesforinfectiousdiseasemanagement
AT dilnawazfahima clinicalperspectiveofchitosannanoparticlesforinfectiousdiseasemanagement
AT acharyasarbari clinicalperspectiveofchitosannanoparticlesforinfectiousdiseasemanagement
AT kanungoanwesha clinicalperspectiveofchitosannanoparticlesforinfectiousdiseasemanagement